



HAL
open science

Ultraviolet exposure regulates skin metabolome based on the microbiome

Vijaykumar Patra, Natalie Bordag, Yohann Clément, Harald Köfeler, Jean-Francois Nicolas, Marc Vocanson, Sophie Ayciriex, Peter Wolf

► **To cite this version:**

Vijaykumar Patra, Natalie Bordag, Yohann Clément, Harald Köfeler, Jean-Francois Nicolas, et al.. Ultraviolet exposure regulates skin metabolome based on the microbiome. *Scientific Reports*, 2023, 13 (1), pp.7207. 10.1038/s41598-023-34073-3 . hal-04091111

HAL Id: hal-04091111

<https://hal.science/hal-04091111v1>



Submitted on 8 Dec 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



OPEN Ultraviolet exposure regulates skin metabolome based on the microbiome

Vijaykumar Patra^{1,2}, Natalie Bordag¹, Yohann Clement³, Harald Köfeler⁴, Jean-Francois Nicolas^{2,5}, Marc Vocanson², Sophie Ayciriex³ & Peter Wolf^{1,6}

Skin metabolites (<1500 Da) play a critical role in barrier function, hydration, immune response, microbial invasion, and allergen penetration. We aimed to understand the global metabolic profile changes of the skin in relation to the microbiome and UV exposure and exposed germ-free (devoid of microbiome), disinfected mice (partially devoid of skin microbiome) and control mice with intact microbiome to immunosuppressive doses of UVB radiation. Targeted and untargeted lipidome and metabolome profiling was performed with skin tissue by high-resolution mass spectrometry. UV differentially regulated various metabolites such as alanine, choline, glycine, glutamine, and histidine in germ-free mice compared to control mice. Membrane lipid species such as phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin were also affected by UV in a microbiome-dependent manner. These results shed light on the dynamics and interactions between the skin metabolome, microbiome, and UV exposure and open new avenues for the development of metabolite- or lipid-based applications to maintain skin health.

Exposure to sunlight, especially the ultraviolet (UV) component, is an important environmental factor affecting human health. UV radiation can penetrate the skin to the dermis (up to 200 μm) and cause both local and systemic changes in molecular and cellular components¹. This can be therapeutically exploited in inflammatory skin diseases in humans on the one hand but can be harmful on the other leading to skin cancer and aging². UV is a potent immunosuppressant, and the underlying immunological mechanisms are widely understood by now, but the impact of skin metabolites and lipids remains elusive.

Metabolites are low molecular weight compounds found in the skin that play a critical role in maintaining the homeostasis³. Skin metabolites originate from sweat, sebum (composed of lipids), interstitial fluid, protein degradation that occurs at the stratum corneum, and intracellular metabolites that play a role in immune responses⁴. Microbes that colonize the skin have a large reservoir of active enzymes that metabolize molecules and further influence the immune response⁵. In our previous work, we showed that the presence or absence of a microbiome determines the effect of UV radiation on cutaneous immune response⁶. In the current study, we investigated the effect of UVB exposure on global skin metabolites and lipids depending on the presence or absence of the microbiome and performed metabolomics and lipidomics analysis on skin biopsies. To investigate if the effects of UV exposure on skin metabolites are dependent on local microbiome or distal gut microbiome, we either used germ free (GF) mice or locally disinfected the UV exposed skin of normal mice. We report a global change in the skin metabolomic and lipidomic profiles induced by UV exposure, which depends on the presence or absence of the skin microbiome.

Results

A single immunosuppressive UVB dose (618 mJ/cm^2) to the skin induces a different transcriptomic signature, cellular infiltrate, and immune response in GF mice compared with control mice⁶. We therefore hypothesized that a similar dose of UVB might also alter the overall metabolic and lipidic profile of the skin, which may contribute to immune modulation in dependence of the microbiome. To test this, we used skin samples from

¹Department of Dermatology, Medical University of Graz, Graz, Austria. ²Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale, U1111, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, UMR5308, Ecole Normale Supérieure de Lyon, Université de Lyon, Lyon, France. ³Université de Lyon, Université Claude Bernard Lyon 1, Institut des Sciences Analytiques, CNRS UMR 5280, 5 rue de la Doua, 69100 Villeurbanne, France. ⁴Core Facility for Mass Spectrometry, Medical University of Graz, Graz, Austria. ⁵Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Lyon, France. ⁶BioTechMed Graz, Graz, Austria. ✉email: vijaykumar.patra@gmail.com; peter.wolf@medunigraz.at

GF mice (n = 6; samples pooled from two independent experiments), mice with depletion of local microbiome by disinfection (n = 5), and control mice (n = 10; samples pooled from two independent experiments), obtained 24 h after UVB exposure (Fig. 1A). The cutaneous metabolome was investigated with targeted and untargeted high resolution mass spectrometry. For statistical analysis a total of 111 targeted lipids and 34 targeted metabolites were extracted, whereas the untargeted data extraction yielded 502 putatively annotated lipids and 3161 unknown features (Fig. 1A).

The absence of microbiome (GF) strongly shifted the cutaneous metabolome compared to control mice with intact microbiome, both before (Fig. 1B,C) and after UVR exposure (Fig. 1D,E) which can be seen from the clear clustering and separation of groups in the supervised multivariate method PLS-DA. Similar results were seen in skin of disinfected mice compared to control mice (Fig. S1A,C). At baseline (unexposed) the metabolic difference is mainly driven by higher lipid levels such as cardiolipins (CL), phosphatidylcholines (PC), phosphatidylethanolamines (PE) or phosphatidylserine (PS) and lower unknown metabolites (Fig. 1C) whereas after UVB exposure it is driven mainly by increase in unknown metabolites (Fig. 1E), comparing GF mice vs. control mice. Independent of the microbiome, the UVB exposure brings the cutaneous metabolomes closer together, as the explained variability (sum of the first two X variates) decreased from 39.5% before (Fig. 1B) to 33.8% after UVB exposure (Fig. 1D). The metabolic shift was notably similar in disinfected skin where the explained variability decreased from 38% before (Fig. S1A) to 36.8% after UVB exposure (Fig. S1C). Analog to GF mice the metabolome of disinfected skin differed significantly from that of control skin before and after UVR exposure (Fig. S1A/C) in both cases mainly driven by unknown metabolites and few increases in glycerophospholipids (Fig. S1B/D). UVR exposure reduced the metabolic differences between non-disinfected skin and disinfected skin, best visible from the univariate LOGLME analysis (Fig. S1E).

Mummichog automated annotation and pathway analysis was used to generate more detailed insights, since most statistically significant metabolic differences were observed in unknown metabolites. Out of 3161 unknown features, 1380 were matched by mummichog for pathway analysis. The pathway analysis revealed that the absence of microbiome consistently diminishes the activity histidine, pyrimidine and alanine/aspartate metabolism among others compared to control mice before (Fig. 1F) and after UVB exposure (Fig. 1G and Supplementary Table S1).


UVB exposure itself induced a strong and significant shift in the overall cutaneous metabolome in both the control mice (Fig. 2A) and the GF mice (Fig. 2C) which was mostly driven by unknown features (Fig. 2B,D). In control mice with an intact microbiome a few selected lipids (e.g., PE O-38:4, PC O-34:0;3O) were increased after UV exposure (Fig. 2B). A detailed analysis with univariate LOGLME underlines how many single significant metabolic differences between control and GF mice become less pronounced or non-significant after UVB exposure (Fig. 2E). The mummichog based pathway analysis shows that in control mice UV exposure increased amino acid metabolism, e.g., Trp, Gly, Ser, Ala, Thr, Ala, Asp, Asn, as well as their amino group metabolism in the urea cycle, while histidine metabolism was decreased together with fatty acid (FA) and sphingolipid metabolism (Fig. 2F). In GF mice fewer pathways were significantly impacted, indicating that the lack of microbiome and microbial metabolism, ameliorates the reaction to UVB. Mainly vitamin B9 metabolism increased, a light sensitive vitamin required for DNA synthesis, while glycosphingolipid metabolism decreased and as in control mice also histidine metabolism decreased (Fig. 2G). We observed similar results in disinfected mice (Fig. S2C) indicating the role of local microbiome in regulating UV-induced metabolic pathways.

In disinfected skin of mice, like in control or GF mice, the UVR exposure significantly and strongly shifted the metabolome (Fig. S2A) which was mainly driven by unknown metabolites and increases in some glycerophospholipids (Fig. S2B). The metabolic shift was notably stronger in disinfected skin than in the skin of control and GF mice judged by the higher x variate percentages of the first two components with a sum of 25.0% control (Fig. 2A) vs. 33.5% GF (Fig. 2C) vs. 47.6% disinfected mice (Fig. S2A).


Pathway analysis further showed that skin disinfection lowered mainly amino acid (Arg, Pro, Asp, Asn) metabolism as well as lipidic mediators-related pathways such as ARA metabolism or putative anti-inflammatory metabolism from EPA. In contrast to the skin of GF mice, histidine metabolism was not significantly impacted in disinfected mice, although trending in the same direction towards being decreased (Fig. S1F and Supplementary Table S1). After UVR exposure the decrease in histidine metabolism became highly significant in disinfected mice (Fig. S1G), in a similar fashion as for GF mice (Fig. 1G). However, the other decreased pathways differed such as urea cycle amino group, Asp, Asn, Arg, Pro, β -Ala amino acid or vitamin B9 metabolism.

Summarized, the cutaneous metabolome strongly depends on the microbiome as seen in unexposed GF and control mice, while UVB exposure reduces microbiome driven metabolic differences.


A Experimental setup




B Control vs GF (UV-)





C




D Control vs GF (UV+)



E



F Control vs GF (UV-)



G Control vs GF (UV+)




Figure 1. Cutaneous metabolome strongly depends on the presence of microbiome before and after UVB exposure. **(A)** Schematic overview of study design. Skin biopsy samples were subjected to metabolomics and lipidomics measurements from which data was extracted in a targeted and untargeted approach as described in methods. **(B)** PLS-DA scores plot investigating the difference of cutaneous metabolome in the absence of any microbiome (GF) before UVB exposure compared to control mice. Each point represents the metabolome of one mouse skin sample and nearness of points represents metabolic similarity. ROC analysis with X variate 1–3 found the metabolomes to differ significantly ($p < 0.001$) with an AUC of 1. The 95% confidence interval of each group is marked by their coloured ellipse. **(C)** Corresponding PLS-DA loadings plot to **(B)**. Each point represents a metabolite’s contribution to the group separation observed in the scores plot **(B)** showing that unknown metabolites strongly differ after UVB exposure. **(D)** PLS-DA scores plot investigating the difference of cutaneous metabolome in the absence of any microbiome (GF) after UVB exposure compared to control mice. Points and ellipse as in Panel B. ROC analysis with X variate 1–3 found the metabolomes to differ significantly ($p < 0.01$) with an AUC of 0.98. **(E)** Corresponding PLS-DA loadings plot to **(D)** [points = metabolites as in **(B)**] showing that unknown metabolites strongly differ after UV exposure. **(F)** Functional analysis of unknown metabolites in the absence of any microbiome (GF) before UVB exposure compared to control mice. Only significantly impacted pathways are labelled ($p < 0.05$). **(G)** Functional analysis of unknown metabolites in the absence of any microbiome (GF) after UVB exposure compared to control mice. Significantly impacted pathways are labelled above the dotted line ($p < 0.05$). $N = 6–10$ mice per experimental group. Data is pooled from two independent experiments.




Figure 2. UVB exposure reduces intra-cutaneous metabolic differences induced by presence/absence of the microbiome. **(A)** PLS-DA scores plot investigating the difference of cutaneous metabolome induced by UVB exposure in control mice. Points and ellipse as in Fig. 1. ROC analysis with X variate 1–3 found the metabolomes to differ significantly ($p < 0.01$) with an AUC of 1. **(B)** Corresponding PLS-DA loadings plot to **(A)** (points = metabolites as in Fig. 1) showing that unknown metabolites strongly differ after UV exposure. **(C)** PLS-DA scores plot investigating the difference of cutaneous metabolome induced by UVB exposure in GF mice. Points and ellipse as in Fig. 1. ROC analysis with X variate 1–3 found the metabolomes to differ significantly ($p < 0.01$) with an AUC of 1. **(D)** Corresponding PLS-DA loadings plot to **(C)** (points = metabolites as in Fig. 1) showing that unknown metabolites strongly differ after UV exposure. **(E)** Dumbbell plot of all significant LOGLME metabolites ($p < 0.05$) in any of the two comparisons: control mice vs GF before UVB exposure (orange) or after UVB exposure (yellow). The plot shows the strength of metabolic changes along the y-axis, significance is encoded in shapes ($p < 0.05$) indicating significant increase (sig. up), decrease (sig. down) or non-significant (non-sig). Note how there are much fewer significant differences after UV exposure (yellow). **(F)** Functional analysis of unknown metabolite changes induced by UVB exposure in control mice. Significantly impacted pathways are labelled above the dotted line ($p < 0.05$). **(G)** Functional analysis of unknown metabolite changes induced by UVB exposure in the absence of any microbiome (GF). Only significantly impacted pathways are labelled ($p < 0.05$). $N = 6–10$ mice per experimental group. Data is pooled from two independent experiments.

Discussion

It is well known that the microbiome plays a critical role in maintaining immune homeostasis and is involved in numerous processes in the skin⁷. To our knowledge, no studies have been performed to understand the complex relationship between UV exposure, skin microbiome, metabolome, and lipidome. Here, we report an altered profile of the global skin metabolome before and after UVB exposure, depending on the microbiome. UV exposure can affect lipids both locally and systemically. A single acute UV irradiation (2–3 MED) is sufficient to induce changes in the lipid profile in the skin, as previously reported⁸. Similarly, we observe changes in both lipid and metabolic profiles in the skin after acute UVB irradiation (2 MED); moreover, we show that these changes depend strongly on the presence or absence of the microbiome. Lipids and lipid metabolism are increasingly recognised as a crucial factor in immune modulation⁹. It is known that several species of the skin microbiome contain enzymes capable of utilising lipids and altering their concentrations on the skin, which could potentially contribute to immunomodulation¹⁰. Our results shed new light on this phenomenon and support this concept.

Metabolites play a critical role in immunomodulation¹¹. Previous studies have focused exclusively on examining specific classes of metabolites⁹, whereas here we provide a much broader and holistic view of the UV-induced metabolic profile of the skin as a function of the microbiome. In the absence of the microbiome, we observe increased ascorbate (vitamin C) and aldarate metabolism in UV-exposed germ-free mice compared to control mice with an intact microbiome. Vitamin C is known to attenuate photoaging, stimulate collagen synthesis, provide antioxidant protection, and have great cosmetic potential¹². In addition, the vitamin B9 or folic acid vitamin pathway was also higher in UV-exposed germ-free and disinfected mice. Folic acid is known to reduce oxidative stress, increase skin hydration, and improve barrier function¹³. On the other hand, we observed lower glycosphingolipid metabolism in UV-exposed germ-free mice. It is known that sphingolipid metabolites play a key role in the regulation and infiltration of immune cells during inflammation¹⁴. These altered metabolic pathways could contribute to the enhanced UV-induced immunosuppression in germ-free and disinfected mice. In the presence of the microbiome, we observe enhanced metabolic pathways such as alanine and aspartate, pyrimidine, nitrogen, glutamate, histidine, and selenoamino acid metabolism. Interestingly, all these metabolic pathways are associated with microbial metabolism¹⁵ and could explain the increase in specific metabolites associated with these pathways in unexposed control mice with intact microbiome compared with germ-free mice. In addition, UV exposure increased tryptophan metabolism in control mice. Although it is difficult to tell from our data whether UV radiation caused an increase in tryptophan metabolites produced by the microbiome or by skin cells. Nevertheless, tryptophan metabolites may exert a regulatory function in inflammation and contribute to UV-induced inflammation in the skin¹⁶. Other metabolic pathways such as glutathione, methionine and cysteine, glycine, serine, alanine and threonine, urea cycle/amino group, alanine, aspartate, and asparagine metabolism induced by UV exposure in control mice may be related to decreased immunosuppression, increased epidermal thickness and cellular infiltrate, and a proinflammatory environment.

Limitations. We used a single, rather high UVB dose (causing systemic immunosuppression); thus, whether lower UVB doses could produce similar results remains to be determined. That said, previous reports of human skin with moderate to severe photodamage show a globally altered metabolic profile¹⁷. A single proinflammatory UV dose (3 MED) modulated skin lipids for up to 14 days post exposure⁸. In vitro experiments with cultured keratinocytes exposed to 20 mJ/cm² of UVB radiation showed altered metabolic activity¹⁸. Taken together, these results suggest that the skin metabolic profile may be dependent on the dose and/or duration of UV exposure. We used a single technique (HPLC–MS) to assess metabolites and lipids and it thus would be desirable to further confirm these specific metabolites and lipids using other advanced techniques such as MS based imaging in the tissue sections^{18,19}. The unexposed skin of GF and disinfected mice differed with regard to certain metabolites and metabolic pathways. We hypothesise that this difference may have been due to the type of disinfectants used, which could have microbiome-independent effects on the metabolome. Indeed, it has been reported that disinfectants or their by-products can alter cellular metabolites²⁰. Moreover differences in microbial load can also influence the metabolic profile of the skin²¹.

Conclusion

Our data provides a good basis for understanding the complex interactions between UV exposure, skin microbiome, metabolome, and lipidome. These results warrant further studies looking in more detail at UV- and/or microbiome-induced specific metabolites or lipids and their effects on the immune response. Identifying such metabolites could lead to development of novel strategies to interfere with specific metabolic pathways to maintain skin “health” after UV exposure.

Methods

Animals. Skin samples were available from animal experiments that were previously performed⁶. Protocols involving the use of germ-free animals were approved by the Regional Animal Research Ethical Board, Stockholm, Sweden (Stockholms norra djurförsöksetiska nämnd), following proceedings described in EU legislation (Council Directive 86/609/EEC). Animal husbandry was done in accordance with Karolinska Institutet guidelines and approved by the above-mentioned board (Ref: N190/15)⁶. Animal experiments adhered to 3R (replacement, reduction, and refinement) policy to ensure use of minimum numbers of animals to maximize data mining⁶. The reporting in the manuscript follows the recommendation in the ARRIVE guidelines.

Skin disinfection model. Shaved dorsal skin of mice was disinfected, as previously described⁶, using freshly prepared 10% or 2% chlorhexidine and 70% isopropyl alcohol, 24 h and 1 h before UVB irradiation and the cages of animals were changed every day through the experimental protocol. Animal care and treatment

protocols were approved by the Austrian Federal Ministry for Science and Research, through protocol number BMWFW-66.010/0137-WF/V/3b/2014. Animal experiments adhered to 3R (replacement, reduction, and refinement) policy to ensure use of minimum numbers of animals to maximize data mining.

UV-B source and exposure. UV irradiation protocol was performed as previously described⁶. The backs of the mice were shaved with electric clippers 24 h before irradiation. UV radiation was administered using a Waldmann 236 light source (Waldmann Medizintechnik, Villingen-Schwenningen, Germany). The light source was equipped with two Waldmann UV6 fluorescent tubes (emission range 280–360 nm; peak 320 nm). The UVB device was positioned upside down on the cage. The mean UVB irradiance of the lamp was 1.9 mW/cm², measured with a Waldmann UV photometer with a UV6 detector head matching the irradiator. A dose of 618 mJ/cm² was administered to each mouse, with an average exposure time of 5 min 42 s. All procedures were performed under sterile conditions in a laminar air-flow unit.

Lipidomics and metabolomics. Our study utilized the same lipidomics and metabolomics methods developed previously²² and as used in various other publications^{23–25}. To ensure consistency and improve the understandability of the results presented in this paper, the method description was retained.

Mouse intra-cutaneous lipid extraction. Lipid extraction was carried out from frozen 3.26–14.7 mg mouse skin biopsies according to a modified version of the original extraction protocol previously published²⁶. Methanol (0.75 mL) and methyl-tert-butyl ether (MTBE, 2.5 mL) were added to the samples in 12 mL glass tubes with teflon lined caps. Tissue was homogenized 30 s using the Ultra-Turrax tissue homogenizer (IKA Works Inc., Wilmington, NC, USA). After vortexing for 10 s, the mixture was incubated in an ice-cooled ultrasound bath for 10 min. After addition of further 0.75 mL methanol and 2.5 mL MTBE samples were shaken in an overhead shaker for 10 min at room temperature. After addition of 1.25 mL deionized water and 10 min of additional overhead shaking, the mixture was centrifuged for 10 min at 1350g (room temperature) and the upper phase was transferred to a new glass tube. The lower phase was re-extracted with 2 mL of the upper phase of MTBE/methanol/deionized water (10:3:2.5, v/v/v) and again the upper phase was collected, combined with the upper phase from the first extraction^{24,25}. Finally, the upper phase was evaporated in a vacuum centrifuge (Thermo Fisher Scientific, Waltham, MA, USA) and dissolved in 500 µL chloroform/methanol (1:1, v/v)^{24,25}. For negative measurement 90 µL aliquots were spiked with 86.3 µL internal standards (chloroform/methanol, 1:1, v/v) containing 12:0/13:0 PI, 17:0/20:4 PI, 14:1/17:0 PI, 21:0/22:6 PI, 12:0/13:0 PG, 17:0/20:4 PG, 14:1/17:0 PG, 21:0/22:6 PG (1.5 µM each) and CL-Mix LM 6003 (2.4 µM). The solvent was evaporated under a gentle stream of nitrogen and the sample reconstituted in the same volume of injection solvent isopropanol/chloroform/methanol (90:5:5, v/v/v)^{24,25}. For positive measurement 2.1 µL aliquots were spiked with 127.7 µL internal standards (chloroform/methanol, 1:1, v/v) containing PC 12:0/13:0, PC 17:0/20:4, PC 14:1/17:0, PC 21:0/22:6 (1 µM each), PE 12:0/13:0, PE 17:0/20:4, PE 14:1/17:0, PE 21:0/22:6, PS 12:0/13:0, PS 17:0/20:4, PS 14:1/17:0, PS 21:0/22:6 (1.5 µM each), TG-Mix LM 6000 (4 µM each), LPC 17:1 (1 µM), SL-Mix LM6002 (1.5 µM each), CE 19:0 (12 µM), and cholesterol-*d*₇ (80 µM) and 36 µL of this mix were used for further processing. The solvent was evaporated under a gentle stream of nitrogen and the sample reconstituted in 90 µL injection solvent isopropanol/chloroform/methanol (90:5:5, v/v/v).

LC-MS/MS lipidomics. Chromatographic separation for sphingolipids was performed as previously described²². Briefly, chromatographic separation was performed on a Waters (Waters, Milford, MA, USA) BEH C8 column (100 × 1 mm, 1.7 µm), thermostatted to 50 °C in a Dionex Ultimate 3000 RS ultra-high-pressure liquid chromatography (UHPLC) system. Mobile phase A was deionized water containing 1 vol% of 1 M aqueous ammonium formate (final concentration 10 mmol/L) and 0.1 vol% of formic acid as additives. Mobile phase B was a mixture of acetonitrile/isopropanol 5:2 (v/v) with the same additives. Gradient elution started at 50% mobile phase B, rising to 100% B over 15 min; 100% B were held for 10 min and the column was re-equilibrated with 50% B for 8 min before the next injection. The flow rate was 150 µL/min, the samples were kept at 8 °C and the injection volume was 2 µL^{22–25,27}.

The Orbitrap Velos Pro hybrid mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) was operated in data dependent acquisition (DDA)^{22–25,27,28}. Every sample was acquired once in positive polarity and once in negative using a HESI II ion source. Ion source parameters for positive polarity were as follows: Source Voltage: 4.5 kV; Source Temperature: 275 °C; Sheath Gas: 25 arbitrary units; Aux Gas: 9 arbitrary units; Sweep Gas: 0 arbitrary units; Capillary Temperature: 300 °C^{22–25,27,28}. Ion source parameters for negative polarity were as follows: Source Voltage: 3.8 kV; Source Temperature: 325 °C; Sheath Gas: 30 arbitrary units; Aux Gas: 10 arbitrary units; Sweep Gas: 0 arbitrary units; Capillary Temperature: 300 °C. Automatic gain control target value was set to 10⁶ ions to enter the mass analyser, with a maximum ion accumulation time of 500 ms. Full scan profile spectra from *m/z* 320 to 1050 for positive ion mode and from 350 to 1600 in negative ion mode were acquired in the Orbitrap mass analyser at a resolution setting of 100,000 at *m/z* 400^{22–25,27,28}. For MS/MS experiments in positive and negative ion mode, the 10 most abundant ions (Top 10) of the full scan spectrum were sequentially fragmented in the ion trap using He as collision gas (CID, Normalized Collision Energy: 50; Isolation Width: 1.5; Activation Q: 0.2; Activation Time: 10) and centroid product spectra at normal scan rate (33 kDa/s) were collected^{22–25,27,28}.

Lipidomics targeted data extraction. LC/MS data were processed using Lipid Data Analyzer (LDA)^{27,29}. Briefly, the algorithm identifies lipids with a 3D algorithm, using the three dimensions *m/z*, retention time, and intensity to correctly integrate peaks, while also considering the isotopic distribution. MS/MS spectra are con-

sidered for confirmation of structures by characteristic head group and fatty acyl fragments. Lipids are annotated according to the official international shorthand nomenclature²⁸.

Metabolite standards. The following substances^{22–25,27,28} were used as references for retention times.

Dopamine HCl (56610-5G; ≥98.5%), L-ornithine monohydrochloride (75469-25G; ≥99.5%), L-prolin (81710-10G; ≥99%), taurine (86330-25G; ≥99%), creatinine (C4255-10G; ≥98%), D-(+)-glucose (G8270-100G; ≥99.5%), L-alanine (A7627-1g; ≥98%), L-asparagine (A0884-25G; ≥98%), L-aspartic acid (A8949-25G; ≥99%), L-citrulline (C7629-10MG; ≥98%), L-glutamic acid (G1251-100G; ≥99%), L-glutamine (G8540-25G; ≥99%), L-histidine (H8000-5G; ≥99%), L-isoleucine (I2752-1G; ≥98%), L-leucine (L8000-25g; ≥98%), L-lysine (L5501-1G; ≥98%), L-methionine sulfoxide (M1126-1G; NA), L-phenylalanine (P2126-100G; ≥98%), L-serine (S4500-1G; ≥99%), L-threonine (T8625-1G; ≥98%), L-tryptophan (T0254-5G; ≥98%), L-tyrosine (T3754-50G; ≥98%), L-valine (V0500-1G; ≥98%), cholic acid (C1129-25G; ≥98%), D-carnitine (544361-1G; ≥98%), decanoyl-L-carnitine (50637-10MG; ≥94%), Folic acid (F7876-1G; ≥97%), hippuric acid (112003-5G; ≥98%), L-carnosine (C9625-10MG; ≥99%), Palmitoyl-L-carnitine (91503-10MG; ≥95%), Riboflavin (R4500-5G; ≥98%), valeryl-L-carnitine (04265-10MG; ≥95%), adenine (A8626-1G; ≥99%), cytidine (C122106-1G; ≥99%), cytosine (C3506-1G; ≥99%), D-arginine (A2646-250MG; ≥98%), choline (C7017-10MG; ≥99%), a-tocopherol (T3251-5G; ≥96%), adenosine (A9251-1G; ≥99%), and methionine (M9625-5G; ≥98%) standards were purchased from Sigma-Aldrich (St. Louis, MO, USA), and Estradiol (E0950-000; NA) from Steraloids (Newport, RI, USA).

Mouse intra-cutaneous metabolite extraction. Sample preparation was performed according to Bruce et al.³⁰, with some modifications. Briefly, mouse skin was homogenized 30 s on ice (4 °C) in 375 µL MeOH/H₂O (1/1, v/v) using the Ultra-Turrax tissue homogenizer (IKA Works Inc., Wilmington, NC, USA). Proteins were precipitated by adding a 3:1 volume of ice-cold acetonitrile/methanol/acetone (1/1/1, v/v/v) and using the Ultra-Turrax again for 30 s on ice. After an additional precipitation step at 4 °C for 60 min, samples were centrifuged at 1 419 relative centrifugal force (rcf) for 10 min (Hereaus Biofuge pico, Hanau, Germany). The resultant supernatants were aspirated into clean Eppendorf tubes and evaporated under a gentle stream of nitrogen gas at room temperature. Dry extracts were re-suspended in acetonitrile/water (1/1, v/v) to 200 µL sample volume, respectively, and immediately stored at –80 °C until further analysis. To evaluate data processing and retention times a mixture of metabolite standard was measured in addition to biological samples. The final injection concentration of these standards was 10 µM solved in acetonitrile/water (1:1, v/v), and the sample reconstituted in 250 µL injection solvent isopropanol.

LC–MS/MS metabolomics. For all samples a full-scan mass-spectrometric interrogation of each sample's small molecule was achieved by Dionex Ultimate 3000 UHPLC (ultra-high performance liquid chromatography)–Orbitrap Velos Pro hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Separation was performed on an Acquity UPLC BEH Amide column (2.1 mm × 150 mm, 1.7 µm) (Waters Corporation, Milford, USA), thermostated to 40 °C. Mobile phase A was 97% ACN + 3% H₂O + 0.1 mM NH₄COOH + 0.16% HCOOH. Mobile phase B was H₂O + 0.1 mM NH₄COOH + 0.16% HCOOH, and autosampler wash solution ACN/H₂O (1:1, v/v). The starting point of gradient elution was 5% mobile phase B and increased up to 30% over 30 min. Mobile phase B was reset to start conditions over a minute and re-equilibrated for 9 min before 2 µL of the next sample was re-injected. Flow rate was 200 µL min^{–1} and samples were thermostated at 8 °C in the autosampler. The Orbitrap Velos Pro operated in data dependent acquisition mode using a HESI II ion source. Full scan spectra from *m/z* 60 to 1600 were acquired in the Orbitrap with a resolution of 100 000 (*m/z* 400) in positive mode and the 10 most abundant ions of the full-scan spectrum were sequentially fragmented with CID (normalized collision energy, 50) and analyzed in the linear ion trap. Isolation width was 1.5, activation Q: 0.2; activation time: 10, and the centroided product spectra at normal scan rate were collected. The exclusion time was set to 11 s and as lock mass a polysiloxane with *m/z* 536.16537 was chosen. The following source parameters were used: Source voltage: 4.5 kV, source temperature: 275 °C, sheath gas: 25 arbitrary units, aux gas: eight arbitrary units, sweep gas: zero arbitrary units, capillary temperature: 300 °C^{22–25,27,28}.

Lipidomics and metabolomics untargeted data extraction. Raw MS data were processed on MS-DIAL software v4.47³¹. First, MS data (.raw) were converted to mzML format with msConvert tool (<http://proteowizard.sourceforge.net>). After conversion, MS-DIAL software was used for feature detection, deconvolution of spectra, peak alignment, and lipid identification³². Briefly, ionization mode (positive and negative), data type (centroided) was selected. For peak detection process, the peak intensity threshold was set up at 1000 of amplitude and the mass slice was set up at 0.1 Da. Linear weighted moving average method was preferred for smoothing (smoothing level 3 scan) and minimum peak width was adjusted to 5. For deconvolution parameters, sigma window value was set up at 0.5. For alignment parameters setting, retention time and MS¹ mass tolerance was selected at 0.05 min and 0.015 Da, respectively. Gap filling function was used for missing value interpolation. Adduct ion setting including protonated molecule, ammonium adduct ion and deprotonated molecule was considered for positive and negative ion mode respectively. For lipid species annotation, MS finder vs 3.52 was used³³.

Lipidomics and metabolomics statistical analysis. Data visualisation and statistical analysis were performed with R v4.2 (using the packages dplyr, openxlsx, readxl, stringr, tibble, tidyr, ggplot2, ggpubr, ggp-misc, ggrepel, ggforce, colorspace, grid, scales, missMDA, mixOmics, nlme, emmeans, rstatix) and TIBCO Spotfire v12.0.1, TIBCO, Palo Alto, CA. All 111 targeted lipids were normalized to their corresponding internal standards and tissue weight of the skin sample yielding absolute quantitative values in pmol/mg. All 34 targeted

metabolites peak areas were integrated yielding arbitrary units and were normalized to tissue weight of the skin sample. Untargeted lipids and metabolites were extracted in arbitrary units. Both targeted and untargeted data did not correlate with tissue weight as checked by Pearson correlation.

Untargeted metabolites and lipids data were trimmed with the very conservative and outlier robust metric MAD score³⁴ of >5 removing very severe single value outliers (<1% data). All features were further filtered for data quality, excluding 126 features with no median standard deviation (MSD) and 146 features with >20% of all values with very low intensity (<10 a.u.) retaining 3663 features for further analysis. Targeted and untargeted data were combined to a total of 3808 metabolites and lipids. The dataset contained no zeros and <2% missing values. All data were log₁₀-transformed (LOG) for statistical analysis to improve distribution and scedasticity. Distribution and scedasticity were investigated with Kolmogorov–Smirnov test and Brown–Forsythe Levene-type test, respectively. All included LOG metabolites and lipids were sufficiently normal and >95% were sufficiently homoscedastic.

Only statistical methods were applied that were able to provide unbiased estimates for the here unbalanced group sizes pooled from independent experiments. Partial least-squares discriminant analysis (PLS-DA) with all features (LOG transformed) was performed after imputation with *missMDA::imputePCA()* using 6 components. Data was further centred and scaled to unit variance with *mixOmics::plsda()* and the multilevel option was used to correct for laboratory differences (factor Exp_ID) for control mice. For readability, the axes of PLS-DA scores and loadings plots have been multiplied by –1, as indicated in the figures, because the classification results or interpretation of the data are independent of direction. Significances of group differences were evaluated with *mixOmics::auROC()*.

Linear mixed models (LME) were fitted with *nlme::lme()* with maximum likelihood (ML) on LOG data (LOGLME) for the factor *group* (control UV–, control UV+, GF UV–, GF UV+, Disinfected UV–, Disinfected UV+) and the laboratory as random factor (~1|Exp_ID), analog to PLS-DA multilevel option. This renders the approach nonlinear mixed models, however due to the name similarity to the *nlme* package name we used LOGLME for clarity. Criteria for model performance and suitability were lower AIC (Akaike information criterion; relative estimate of information loss), higher log-likelihood (goodness of fit), significance in log likelihood ratio test comparing two models, quality of Q–Q plots and randomness in residual plots. The addition of the random factor had no influence on model performance or results in ~84% of all metabolites and lipids but improved performance significantly for the remainder 16%. For consistency and comparability between metabolites and lipids only results from models with random factor are reported. Post-hoc pairwise comparisons were readout with *emmeans::emmeans*, and *p* ≤ 0.05 were considered statistically significant. All reported *p*-values were adjusted for multiple testing according to Benjamini–Hochberg (BH) (R function *stats::p.adjust*).

Pathway analysis was performed online with the functional analysis module from MetaboAnalyst 5.0³⁵ using mummichog-based annotation for all positive, untargeted features providing exact masses and retention times with a mass tolerance of 5 ppm without further feature filtering. Data was LOG transformed but no further normalizations or scalings were performed in Metaboanalyst. Normalized enrichment score (NES) analysis was performed for each pairwise group comparison based on the 1388–1391 compound matches with the GSEA algorithm on the mummichog original MFN library for pathways with at least 3 entries.

Data availability

Untargeted lipidomics and metabolomics data have been deposited to the EMBL-EBI MetaboLights database with the identifier MTBLS6969. The data sets can be accessed here: <https://www.ebi.ac.uk/metabolights/MTBLS6969>.

Received: 21 February 2023; Accepted: 24 April 2023

Published online: 03 May 2023

References

- Bernard, J. J., Gallo, R. L. & Krutmann, J. Photoimmunology: How ultraviolet radiation affects the immune system. *Nat. Rev. Immunol.* **19**, 688–701. <https://doi.org/10.1038/s41577-019-0185-9> (2019).
- Vieyra-Garcia, P. A. & Wolf, P. A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer. *Pharmacol. Ther.* **222**, 107784. <https://doi.org/10.1016/j.pharmthera.2020.107784> (2021).
- Elpa, D. P., Chiu, H. Y., Wu, S. P. & Urban, P. L. Skin metabolomics. *Trends Endocrinol. Metab.* **32**, 66–75. <https://doi.org/10.1016/j.tem.2020.11.009> (2021).
- Cibrian, D., de la Fuente, H. & Sanchez-Madrid, F. Metabolic pathways that control skin homeostasis and inflammation. *Trends Mol. Med.* **26**, 975–986. <https://doi.org/10.1016/j.molmed.2020.04.004> (2020).
- Chen, H. *et al.* Skin microbiome, metabolome and skin phenotype, from the perspectives of skin as an ecosystem. *Phenomics* **2**, 363–382. <https://doi.org/10.1007/s43657-022-00073-y> (2022).
- Patra, V., Wagner, K., Arulampalam, V. & Wolf, P. Skin microbiome modulates the effect of ultraviolet radiation on cellular response and immune function. *iScience* **15**, 211–222. <https://doi.org/10.1016/j.isci.2019.04.026> (2019).
- Flowers, L. & Grice, E. A. The skin microbiota: Balancing risk and reward. *Cell Host Microbe* **28**, 190–200. <https://doi.org/10.1016/j.chom.2020.06.017> (2020).
- Hawkshaw, N. J. *et al.* UV radiation recruits CD4(+)GATA3(+) and CD8(+)GATA3(+) T cells while altering the lipid microenvironment following inflammatory resolution in human skin in vivo. *Clin. Transl. Immunol.* **9**, e01104. <https://doi.org/10.1002/cti2.1104> (2020).
- Tse, B. C. Y. & Byrne, S. N. Lipids in ultraviolet radiation-induced immune modulation. *Photochem. Photobiol. Sci.* **19**, 870–878. <https://doi.org/10.1039/d0pp00146e> (2020).
- Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. *Nat. Rev. Microbiol.* **16**, 143–155. <https://doi.org/10.1038/nrmicro.2017.157> (2018).
- Chu, X. *et al.* Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease. *Genome Biol.* **22**, 198. <https://doi.org/10.1186/s13059-021-02413-z> (2021).
- Boo, Y. C. Ascorbic acid (vitamin C) as a cosmeceutical to increase dermal collagen for skin antiaging purposes: Emerging combination therapies. *Antioxidants (Basel)* **11**, 1663. <https://doi.org/10.3390/antiox11091663> (2022).

13. Gisondi, P., Fantuzzi, F., Malerba, M. & Girolomoni, G. Folic acid in general medicine and dermatology. *J. Dermatolog. Treat.* **18**, 138–146. <https://doi.org/10.1080/09546630701247930> (2007).
14. Maceyka, M. & Spiegel, S. Sphingolipid metabolites in inflammatory disease. *Nature* **510**, 58–67. <https://doi.org/10.1038/nature13475> (2014).
15. Yu, G., Xu, C., Zhang, D., Ju, F. & Ni, Y. MetOrigin: Discriminating the origins of microbial metabolites for integrative analysis of the gut microbiome and metabolome. *iMeta* **1**, e10. <https://doi.org/10.1002/imt2.10> (2022).
16. Helferich, W. G. & Denison, M. S. Ultraviolet photoproducts of tryptophan can act as dioxin agonists. *Mol. Pharmacol.* **40**, 674–678 (1991).
17. Randhawa, M., Sangar, V., Tucker-Samaras, S. & Southall, M. Metabolic signature of sun exposed skin suggests catabolic pathway overweighs anabolic pathway. *PLoS One* **9**, e90367. <https://doi.org/10.1371/journal.pone.0090367> (2014).
18. Kremslehner, C. *et al.* Imaging of metabolic activity adaptations to UV stress, drugs and differentiation at cellular resolution in skin and skin equivalents—Implications for oxidative UV damage. *Redox Biol.* **37**, 101583. <https://doi.org/10.1016/j.redox.2020.101583> (2020).
19. Buchberger, A. R., DeLaney, K., Johnson, J. & Li, L. Mass spectrometry imaging: A review of emerging advancements and future insights. *Anal. Chem.* **90**, 240–265. <https://doi.org/10.1021/acs.analchem.7b04733> (2018).
20. Meintani, D. G., Chatzimitakos, T. G., Kasouni, A. I. & Stalikas, C. D. Untargeted metabolomics of human keratinocytes reveals the impact of exposure to 2,6-dichloro-1,4-benzoquinone and 2,6-dichloro-3-hydroxy-1,4-benzoquinone as emerging disinfection by-products. *Metabolomics* **18**, 89. <https://doi.org/10.1007/s11306-022-01935-2> (2022).
21. Roux, P. F., Oddos, T. & Stamatias, G. Deciphering the role of skin surface microbiome in skin health: An integrative multiomics approach reveals three distinct metabolite-microbe clusters. *J. Investig. Dermatol.* **142**, 469–479 e465. <https://doi.org/10.1016/j.jid.2021.07.159> (2022).
22. Triebl, A., Trotzmüller, M., Hartler, J., Stojakovic, T. & Kofeler, H. C. Lipidomics by ultrahigh performance liquid chromatography-high resolution mass spectrometry and its application to complex biological samples. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **1053**, 72–80. <https://doi.org/10.1016/j.jchromb.2017.03.027> (2017).
23. Zullig, T. *et al.* A metabolomics workflow for analyzing complex biological samples using a combined method of untargeted and target-list based approaches. *Metabolites* **10**, 342. <https://doi.org/10.3390/metabo10090342> (2020).
24. Zandl-Lang, M. *et al.* Changes in the cerebrospinal fluid and plasma lipidome in patients with Rett syndrome. *Metabolites* **12**, 291. <https://doi.org/10.3390/metabo12040291> (2022).
25. Zhang, Y. *et al.* Asymmetric opening of the homopentameric 5-HT(3A) serotonin receptor in lipid bilayers. *Nat. Commun.* **12**, 1074. <https://doi.org/10.1038/s41467-021-21016-7> (2021).
26. Matyash, V., Liebisch, G., Kurzchalia, T. V., Shevchenko, A. & Schwudke, D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. *J. Lipid Res.* **49**, 1137–1146. <https://doi.org/10.1194/jlr.D700041-JLR200> (2008).
27. Hartler, J. *et al.* Lipid Data Analyzer: Unattended identification and quantitation of lipids in LC-MS data. *Bioinformatics* **27**, 572–577. <https://doi.org/10.1093/bioinformatics/btq699> (2011).
28. Liebisch, G. *et al.* Shorthand notation for lipid structures derived from mass spectrometry. *J. Lipid Res.* **54**, 1523–1530. <https://doi.org/10.1194/jlr.M033506> (2013).
29. Hartler, J. *et al.* Deciphering lipid structures based on platform-independent decision rules. *Nat. Methods* **14**, 1171–1174. <https://doi.org/10.1038/nmeth.4470> (2017).
30. Bruce, S. J. *et al.* Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. *Anal. Chem.* **81**, 3285–3296. <https://doi.org/10.1021/ac8024569> (2009).
31. Tsugawa, H. *et al.* A lipidome atlas in MS-DIAL 4. *Nat. Biotechnol.* **38**, 1159–1163. <https://doi.org/10.1038/s41587-020-0531-2> (2020).
32. Tsugawa, H. *et al.* A cheminformatics approach to characterize metabolomes in stable-isotope-labeled organisms. *Nat. Methods* **16**, 295–298. <https://doi.org/10.1038/s41592-019-0358-2> (2019).
33. Lai, Z. *et al.* Identifying metabolites by integrating metabolome databases with mass spectrometry cheminformatics. *Nat. Methods* **15**, 53–56. <https://doi.org/10.1038/nmeth.4512> (2018).
34. Leys, C., Ley, C., Klein, O., Bernard, P. & Licata, L. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. *J. Exp. Soc. Psychol.* **49**, 764–766. <https://doi.org/10.1016/j.jesp.2013.03.013> (2013).
35. Pang, Z. *et al.* MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. *Nucleic Acids Res.* **49**, W388–W396. <https://doi.org/10.1093/nar/gkab382> (2021).

Acknowledgements

We thank Velmurugesan Arulampalam, Johanna Aspsater and Josefine Rosén, CGFR, KI, for their support for the GF animal experiments and technical support.

Author contributions

V.P.: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing—original draft. N.B.: Software, Validation, Methodology, Visualization, Writing—original draft, review and editing. Y.C.: Software, Validation, Methodology, Writing—review and editing. H.K.: Methodology. J.-F.N.: Writing—review and editing. M.V.: Writing—review and editing. S.A.: Software, Validation, Methodology, Writing—review and editing. P.W.: Formal analysis, Funding acquisition, Methodology, Resources, Supervision, Validation, Writing—review and editing.

Funding

VP received financial support from the City of Graz for this project. PW received support from the Austrian Science Fund (FWF, W1241). The funders had no role in the study design, data collection or interpretation, or the decision to submit the work for publication.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-34073-3>.

Correspondence and requests for materials should be addressed to V.P. or P.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023